

My Approach to a Patient with Metastatic Colorectal Cancer

Daniel B. Brown, MD FSIR

CRC Tumor Board

Professor of Radiology and Biomedical Engineering

Vice-Chair, Innovation and Clinical Research

Director, Interventional Oncology

Vanderbilt University Medical Center

Disclosures

Consultant – Becton-Dickinson, Sirtex

Grant/Research Support – Sirtex, Boston Scientific

Brand names are included in this presentation for participant clarification purposes only. No product promotion should be inferred.


52 YO AA Male
Rectal cancer Dx 12/2015
Simultaneous lung/liver mets
KRAS wild type/MSS


Rectal XRT then FOLFOX 2 months: PD

XRT for lytic femoral metastasis
FOLFIRI 12 cycles, PD on maintenance
Refer to IR


Pt back on FOLFIRI
Replaced a cycle with Y90







6-Month Return to Clinic: Increased Dyspnea



87 YO female


3/2015: Left CRC resected OSH



Stage II, no adjuvant therapy given

12/2016: 4 cm liver metastasis identified



6 cycles FOLFOX prior to resection

Pt complaining of nausea/dysphagia







Plan: Repair Paraesophageal Hernia
LRT test of time. Allow resection after recovery




MIRD	Dose	Activity
Tumour	180.9 Gy	0.5 GBq
Liver	45.2 Gy	0.1 GBq
Lung	2.0 Gy	0.0 GBq
Total		0.6 GBq


57 YO F:
Synchronous met
Stable disease after FOLFOX
MSS
KRAS Wild Type
CEA 63

Referred for consideration
of LRT to boost
first-line response






Original Treatment Plan



Modified Treatment Plan



Treated
on
5-FU

2-Month CT Scan



CEA: 63 → 9

Maintenance Continued for 11 Months

38-Year-Old Male


2017:
Abd Pain
Abnormal LFTs
PET IDs sigmoid primary
MSS, RAS/RAF Wild Type
12 cycles FOFIRI
On/off Avastin for proteinuria




ALPPS 4/30/18 including
LLS wedge

2nd portion 5/8/18

Colectomy/loop ileostomy
7/18



10/18: first post-op scan




10/18: First post-op scan
FOLFIRI 11/18 →

Progressed on therapy 12/18

FOLFOX progressed 5/19

Panitumumab 8/19




Referred to IR 9/19:


On panitumumab
LFTs normal

Treatment options?






VANDERBILT  UNIVERSITY
MEDICAL CENTER






CEA: 8 → 2


VANDERBILT  UNIVERSITY
MEDICAL CENTER



CEA: 8 → 2 → 12 at 6
Months

VANDERBILT  UNIVERSITY
MEDICAL CENTER







2012: T3 CRC (KRAS WT)
Didn't tolerate
adjuvant CapeOX

2015: CapeOX/Avastin
Liver and peritoneal
met resected

2016: new liver met
Back on CapeOX
Referred to IR




FLR 25% of TLV




PVE 7/2016





1800 cc


VANDERBILT  UNIVERSITY
MEDICAL CENTER



810 cc





FLR now: 45%




2/2020:
New liver mets
in remnant

All segments involved
Low tumor volume




Oncozene 100 mcm
100 mg IRI



Intense Pain:
CT next day

7 weeks since
last imaging

Clear progression



Right lobe treated
5 weeks later
100 mcm Oncozene
100 mg IRI

